{"id":"https://openalex.org/W2043749332","doi":"https://doi.org/10.1021/jm300025r","title":"Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas","display_name":"Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas","publication_year":2012,"publication_date":"2012-05-02","ids":{"openalex":"https://openalex.org/W2043749332","doi":"https://doi.org/10.1021/jm300025r","mag":"2043749332","pmid":"https://pubmed.ncbi.nlm.nih.gov/22551018"},"language":"en","primary_location":{"id":"doi:10.1021/jm300025r","doi":"https://doi.org/10.1021/jm300025r","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm300025r","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003196865","display_name":"Vibha B. Oza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Vibha Oza","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108554420","display_name":"Susan Ashwell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Ashwell","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103467579","display_name":"Lynsie Almeida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lynsie Almeida","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049065288","display_name":"Patrick J. Brassil","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Brassil","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078542177","display_name":"Jason Breed","orcid":"https://orcid.org/0000-0002-3379-0948","observed_orcids":["https://orcid.org/0000-0002-3379-0948"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jason Breed","raw_affiliation_strings":["AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Chun Deng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chun Deng","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066313823","display_name":"Thomas W. Gero","orcid":"https://orcid.org/0009-0003-3770-8061","observed_orcids":["https://orcid.org/0009-0003-3770-8061"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Gero","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049708947","display_name":"Michael R. Grondine","orcid":"https://orcid.org/0000-0001-7806-1864","observed_orcids":["https://orcid.org/0000-0001-7806-1864"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Grondine","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090689034","display_name":"Candice L. Horn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Candice Horn","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042359123","display_name":"Stephanos Ioannidis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanos Ioannidis","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084853102","display_name":"Dongfang Liu","orcid":"https://orcid.org/0000-0002-8801-2190","observed_orcids":["https://orcid.org/0000-0002-8801-2190","https://orcid.org/0009-0001-9241-2218","https://orcid.org/0009-0001-3699-4751"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dongfang Liu","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016791761","display_name":"Paul D. Lyne","orcid":"https://orcid.org/0000-0003-0861-9134","observed_orcids":["https://orcid.org/0000-0003-0861-9134"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Lyne","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086631777","display_name":"Nicholas J. Newcombe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nicholas Newcombe","raw_affiliation_strings":["AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051322178","display_name":"Martin Pass","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin Pass","raw_affiliation_strings":["AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033356973","display_name":"Jon A. Read","orcid":"https://orcid.org/0000-0002-6944-3702","observed_orcids":["https://orcid.org/0000-0002-6944-3702"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jon Read","raw_affiliation_strings":["AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000162965","display_name":"Shannon Ready","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shannon Ready","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084679429","display_name":"Si\u00e2n Rowsell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Si\u00e2n Rowsell","raw_affiliation_strings":["AstraZeneca R&D, Macclesfield SK10 2NA, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D, Macclesfield SK10 2NA, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108542418","display_name":"Mei Su","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mei Su","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078687678","display_name":"Dorin Toader","orcid":"https://orcid.org/0000-0001-6330-5280","observed_orcids":["https://orcid.org/0000-0001-6330-5280"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dorin Toader","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054565788","display_name":"Melissa M. Vasbinder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Vasbinder","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102427911","display_name":"Dingwei Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dingwei Yu","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075661506","display_name":"Yan Yu","orcid":"https://orcid.org/0000-0002-5478-1733","observed_orcids":["https://orcid.org/0000-0002-5478-1733"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Yu","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024535671","display_name":"Yafeng Xue","orcid":"https://orcid.org/0000-0002-7526-8672","observed_orcids":["https://orcid.org/0000-0002-7526-8672"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Yafeng Xue","raw_affiliation_strings":["AstraZeneca R&D M\u00f6lndal, SE-43183 M\u00f6lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D M\u00f6lndal, SE-43183 M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111904185","display_name":"Sonya Zabludoff","orcid":"https://orcid.org/0000-0003-1786-6241","observed_orcids":["https://orcid.org/0000-0003-1786-6241"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sonya Zabludoff","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049539326","display_name":"James W. Janetka","orcid":"https://orcid.org/0000-0002-9888-5411","observed_orcids":["https://orcid.org/0000-0002-9888-5411"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Janetka","raw_affiliation_strings":["AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5003196865"],"corresponding_institution_ids":["https://openalex.org/I4210150756"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":3.7308,"has_fulltext":false,"cited_by_count":74,"citation_normalized_percentile":{"value":0.94623089,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"55","issue":"11","first_page":"5130","last_page":"5142"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.4036000072956085,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.4036000072956085,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.34299999475479126,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.10660000145435333,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/azd7762","display_name":"AZD7762","score":0.9760000109672546},{"id":"https://openalex.org/keywords/chk1-inhibitor","display_name":"CHK1 inhibitor","score":0.7139999866485596},{"id":"https://openalex.org/keywords/chk2","display_name":"Chk2","score":0.6610000133514404},{"id":"https://openalex.org/keywords/structure-based-drug-design","display_name":"structure-based drug design","score":0.9390000104904175},{"id":"https://openalex.org/keywords/jnk1","display_name":"JNK1","score":0.6159999966621399},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.7860000133514404},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.8349999785423279},{"id":"https://openalex.org/keywords/chemosensitization","display_name":"chemosensitization","score":0.8190000057220459},{"id":"https://openalex.org/keywords/high-throughput-screening-hits","display_name":"high-throughput screening hits","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C50001416","wikidata":"https://www.wikidata.org/wiki/Q17861750","display_name":"CHEK1","level":5,"score":0.8968197107315063},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.706129252910614},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.6392230987548828},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.6015197038650513},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.5929635763168335},{"id":"https://openalex.org/C54086632","wikidata":"https://www.wikidata.org/wiki/Q5512671","display_name":"G2-M DNA damage checkpoint","level":5,"score":0.4597565829753876},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.41445648670196533},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.41011035442352295},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.3917301893234253},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3898693025112152},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36176520586013794},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.34245920181274414},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.33333876729011536},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2941349744796753},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2163427770137787},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.1759515404701233},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15116283297538757}],"mesh":[{"descriptor_ui":"D000071877","descriptor_name":"Checkpoint Kinase 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000093542","descriptor_name":"Gemcitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001665","descriptor_name":"Binding Sites","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004249","descriptor_name":"DNA Damage","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008958","descriptor_name":"Models, Molecular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013237","descriptor_name":"Stereoisomerism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014508","descriptor_name":"Urea","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018360","descriptor_name":"Crystallography, X-Ray","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057166","descriptor_name":"High-Throughput Screening Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm300025r","doi":"https://doi.org/10.1021/jm300025r","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm300025r","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:22551018","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22551018","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.8048999905586243,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1837329986","https://openalex.org/W1965221441","https://openalex.org/W1973785732","https://openalex.org/W1977426520","https://openalex.org/W1979986967","https://openalex.org/W1980010870","https://openalex.org/W1985701256","https://openalex.org/W1986191025","https://openalex.org/W1996505651","https://openalex.org/W1999286871","https://openalex.org/W2002696717","https://openalex.org/W2015679656","https://openalex.org/W2031342779","https://openalex.org/W2046109115","https://openalex.org/W2049451509","https://openalex.org/W2051744391","https://openalex.org/W2055651767","https://openalex.org/W2067614594","https://openalex.org/W2095986441","https://openalex.org/W2097173890","https://openalex.org/W2105768236","https://openalex.org/W2105979581","https://openalex.org/W2109099502","https://openalex.org/W2109554640","https://openalex.org/W2110698289","https://openalex.org/W2126583326","https://openalex.org/W2135946515","https://openalex.org/W2139291133","https://openalex.org/W2153574313","https://openalex.org/W2158648773","https://openalex.org/W2162730779","https://openalex.org/W2169365607","https://openalex.org/W2316582027","https://openalex.org/W2412852597","https://openalex.org/W2949108634"],"related_works":["https://openalex.org/W1977426520","https://openalex.org/W2781619621","https://openalex.org/W1989150405","https://openalex.org/W2416730013","https://openalex.org/W2281059672","https://openalex.org/W2049451509","https://openalex.org/W2023313378","https://openalex.org/W1968321016","https://openalex.org/W4205166053","https://openalex.org/W3087709341"],"abstract_inverted_index":{"Checkpoint":[0],"kinases":[1],"CHK1":[2,53,69,86],"and":[3,43,68,74,76,96],"CHK2":[4],"are":[5],"activated":[6],"in":[7,14,70,112,145],"response":[8],"to":[9,27,34,89,125],"DNA":[10,22],"damage":[11],"that":[12,25],"results":[13],"cell":[15],"cycle":[16],"arrest,":[17],"allowing":[18],"sufficient":[19],"time":[20],"for":[21],"repair.":[23],"Agents":[24],"lead":[26,119],"abrogation":[28],"of":[29,38,52,66,77,85,109,115,122,128,139,142],"such":[30,39],"checkpoints":[31],"have":[32],"potential":[33],"increase":[35],"the":[36,78,105,113,126,129,137],"efficacy":[37,138],"compounds":[40],"as":[41,50],"chemo-":[42],"radiotherapies.":[44],"Thiophenecarboxamide":[45],"ureas":[46],"(TCUs)":[47],"were":[48],"identified":[49],"inhibitors":[51,91],"by":[54],"high":[55],"throughput":[56],"screening.":[57],"A":[58],"structure-based":[59],"approach":[60],"is":[61],"described":[62],"using":[63],"crystal":[64],"structures":[65],"JNK1":[67],"complex":[71],"with":[72,92],"1":[73],"2":[75],"CHK1-3b":[79],"complex.":[80],"The":[81],"ribose":[82],"binding":[83],"pocket":[84],"was":[87],"targeted":[88],"generate":[90],"excellent":[93],"cellular":[94],"potency":[95],"selectivity":[97],"over":[98],"CDK1and":[99],"IKK\u03b2,":[100],"key":[101],"features":[102],"lacking":[103],"from":[104],"initial":[106],"compounds.":[107],"Optimization":[108,121],"3b":[110],"resulted":[111],"identification":[114],"a":[116,140],"regioisomeric":[117],"3-TCU":[118],"12a.":[120],"12a":[123],"led":[124],"discovery":[127],"clinical":[130],"candidate":[131],"4":[132],"(AZD7762),":[133],"which":[134],"strongly":[135],"potentiates":[136],"variety":[141],"DNA-damaging":[143],"agents":[144],"preclinical":[146],"models.":[147]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}